⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL9693044 | 0.97 | — | — | |
| SCHEMBL25774454 | 0.91 | — | — | |
| Bromide SCHEMBL9736341 | 0.80 | — | — | |
| Bromide SCHEMBL9737718 | 0.80 | MAOA (0.37) | — | |
| Hydrochloric Acid SCHEMBL9738968 | 0.80 | — | — | |
| SCHEMBL14212477 | 0.77 | — | — | |
| SCHEMBL11997023 | 0.75 | — | — | |
| Bromide SCHEMBL9736200 | 0.72 | — | — | |
| SCHEMBL10360616 | 0.69 | TOP2A (0.31) | — | |
| SCHEMBL16456457 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348486-A1 | NEAR-INFRARED EMITTING PORPHYRIN COMPOUND AND PREPARATION METHOD AND USE THEREOF | PEKING UNIVERSITY (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2023089074-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR A SYSTEMIC TREATMENT OF DISEASES AND CONDITIONS | Samsara Therapeutics Inc. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2021055668-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2020139916-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| US-10246470-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2019-04-02 | — | — | US | disclosed |
| US-20180215765-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-08-02 | — | — | US | disclosed |
| US-10011609-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2018-07-03 | — | — | US | disclosed |
| US-10011609-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2018-07-03 | — | — | US | disclosed |
| EP-2473041-B1 | MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20160257701-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2016-09-08 | — | — | US | disclosed |
| US-20160257701-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2016-09-08 | — | — | US | disclosed |
| WO-2015097713-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2015-07-02 | — | — | WO | disclosed |
| US-8993535-B2 | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20120184505-A1 | MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-19 | — | — | US | disclosed |
| EP-0424851-A1 | Quinolone compounds and a process for their preparation | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1991-05-02 | — | — | EP | disclosed |